載入...
Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer
The loss-of-function mutation of formyl peptide receptor 1 (FPR1) has a negative impact on the progression-free and overall survival of breast cancer patients treated with anthracycline-based adjuvant chemotherapy. This effect may be attributed to the fact that chemotherapy-induced antitumor immunit...
Na minha lista:
| 發表在: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Taylor & Francis
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4938360/ https://ncbi.nlm.nih.gov/pubmed/27471610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1139275 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|